FTT PET/CT in Pancreatic Neuroendocrine Tumors — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

FTT PET/CT in Pancreatic Neuroendocrine Tumors — Stella

Home/Neuroendocrine Carcinoma Metastatic/

View on ClinicalTrials.gov

Recruiting

Back to Neuroendocrine Carcinoma Metastatic trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania

Key details

Phase

Early testing

Sponsor

Abramson Cancer Center at Penn Medicine

Collaborators

University of Pennsylvania

Enrollment target

~12 participants

Started

October 2025

Primary completion

September 2027

Age range

18 Years and older

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.